A Pilot Study of the Mechanism of Action of Desipramine

1981 ◽  
Vol 138 (3) ◽  
pp. 248-251 ◽  
Author(s):  
S. A. Checkley ◽  
A. P. Slade ◽  
E. Shur ◽  
S. Dawling
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Pilot Study ◽  
Mechanism Of Action ◽  
Depressed Patients ◽  
Sedative Effects ◽  
Before And After ◽  
Hormone Responses

SummaryTo test the hypothesis that desipramine alters α adrenoceptor function in depressed patients, the effects of clonidine upon growth hormone sedation and blood pressure have been measured in depressed patients before and after treatment with desipramine. After three weeks of treatment the hypotensive and sedative effects of clonidine were inhibited in all patients even though plasma desipramine concentrations at this time varied from 42 to 560 μg/l. Growth hormone responses to clonidine were enhanced in five of the six patients but this effect was not statistically significant. These findings are consistent with the hypothesis that in these patients desipramine altered α adrenoceptor function: other explanations are discussed.

Growth Hormone Responses to Growth Hormone-Releasing Hormone and Clonidine before and after Erythropoietin Therapy in CAPD Patients

Nephron ◽  
1996 ◽  
Vol 74 (3) ◽  
pp. 548-554 ◽  
Author(s):  
Juan J. Díez ◽  
Pedro Iglesias ◽  
Julia Sastre ◽  
Javier Méndez ◽  
Rafael Selgas ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Before And After ◽  
Hormone Responses

scholarly journals Borassus aethiopum-Fortified Bread Reduces Metabolic Risk Factors among Cardiovascular Disease Outpatients at 37 Military Hospital, Accra: A Pilot Study

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Charles Apprey ◽  
Marian Peprah ◽  
Reginald Adjetey Annan ◽  
Marina A. Tandoh ◽  
Odeafo Asamoah-Boakye
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Pilot Study ◽  
Controlled Trial ◽  
Metabolic Risk Factors ◽  
Military Hospital ◽  
Metabolic Risk ◽  
Before And After ◽  
Experimental Group ◽  
Borassus Aethiopum

Background. Dyslipidemia and hypertension are the leading causes of morbidity and mortality in patients with cardiovascular diseases (CVDs). Objective. The study sought to evaluate the effects of Borassus aethiopum-fortified bread on metabolic risk factors among CVD outpatients. Method. From August 2016 to April 2017, a pilot study using a single-blinded randomized placebo-controlled trial was conducted by administering Borassus-fortified bread (150 g) and indistinguishable placebo (150 g white flour bread) daily to 122 CVD outpatients at 37 Military Hospital, Accra, Ghana, for 90 days. Body composition, blood pressure, and biochemical parameters were evaluated before and after the intervention. Results. Following the intervention, the mean waist circumference (before: 98.3±14.6 cm, after: 95.9±15.8 cm, P=0.030), BMI (before: 31.4±6.9 kg/m2, after: 28.0±5.8 kg/m2, P=0.027), and visceral fat (before: 10.4±3.2, after: 9.9±3.0, P=0.013), as well as systolic (from 161.2±25.5 to 137.6±22.9and diastolic (from 99.2±13.6 to 85.1±10.8) blood pressure, were significantly reduced among the experimental group. Likewise, serum total cholesterol (TC), LDL, and HDL were significantly reduced within the experimental group before (TC: 5.9±1.1, LDL: 3.4±1.1, and HDL: 2.2±0.5) and after the intervention (TC: 4.9±1.1, LDL: 2.8±0.9, and HDL: 1.5±0.4) (TC: P=0.001, LDL: P=0.016, and HDL: P < 0.001, in mmol/L). These reductions were not observed in the controls. Conclusion. The Borassus-fortified bread significantly reduced blood pressure and improved lipid profile and other metabolic risk factors among the CVD outpatients studied. Therefore, its potential in the management of CVDs and other metabolic-related diseases should be looked at.

Effects of Clonidine on Blood Pressure, Noradrenaline, Cortisol, Growth Hormone, and Prolactin Plasma Levels in High and Low Intestinal Tone Depressed Patients

1985 ◽  
Vol 41 (2) ◽  
pp. 156-162 ◽  
Author(s):  
Fuad Lechin ◽  
Bertha van der Dijs ◽  
Daniela Jakubowicz ◽  
Rheyna E. Camero ◽  
Simon Villa ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Plasma Levels ◽  
Depressed Patients

Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Liat Perl ◽  
Erella Elkon-Tamir ◽  
Anat Segev-Becker ◽  
Galit Israeli ◽  
Avivit Brener ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Pilot Study ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Estrogen Treatment ◽  
Female Adolescents ◽  
Estradiol Treatment ◽  
Releasing Hormone ◽  
Before And After ◽  
Hormone Analogs

Abstract Objectives The benefits of gonadotropin-releasing hormone analogues (GnRHa) in the treatment of central precocious puberty are well established, and their use is regarded as both safe and effective. Possible adverse effects on blood pressure (BP) and cardiac outcomes, body composition, bone health and brain development, however, continue to be of some concern. The aim of this study was to analyze BP changes in transgender female adolescents before and after receiving GnRHa and after adding estrogen treatment. Methods This was a retrospective pilot study. We analyzed systolic BP (SBP) and diastolic BP (DBP) before and after GnRHa initiation and after adding estrogen. Results Nineteen transgender female adolescents received GnRHa and 15 continued to estrogen treatment. Their baseline SBP and DBP percentiles did not change significantly after either GnRHa or the addition of estrogen treatment. Conclusions Blood pressure is apparently not affected by GnRHa or GnRHa + estrogen treatment in transgender female adolescents. Further larger studies are indicated to confirm these findings.

A Single Growth Hormone Determination to Rule Out Growth Hormone Deficiency

PEDIATRICS ◽  
1977 ◽  
Vol 59 (3) ◽  
pp. 467-468
Author(s):  
Ann J. Johanson ◽  
Gordon L. Morris
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Hormone Deficiency ◽  
University Of Virginia ◽  
Vigorous Exercise ◽  
Exercise Tests ◽  
Before And After ◽  
Hormone Responses ◽  
The University ◽  
Rule Out

Exercise is a known stimulus to growth hormone release1 and has been used effectively as a screening test for growth hormone deficiency.2,3 On the pediatric endocrine service at the University of Virginia, 87 exercise tests have been performed to determine growth hormone responses in 72 children and adolescents (74 tests), 2 to 19 years old, and 13 adults, 23 to 67 years old (Table I). Two children were tested twice. After at least four hours of fasting, blood was obtained for growth hormone determinations before and after 20 minutes of sustained, vigorous exercise to near exhaustion (rapid walking, running on inclined treadmill, or climbing stairs), and 20 minutes after cessation of exercise, modified according to Keenan et al.4

Enhanced Growth Hormone Responses to TRH Injection in Bipolar Depressed Patients

1975 ◽  
Vol 29 (3) ◽  
pp. 215-220 ◽  
Author(s):  
Saburo Takahashi ◽  
Hisao Kondo ◽  
Manabu Yoshimura
Keyword(s):  
Growth Hormone ◽  
Depressed Patients ◽  
Hormone Responses

Effects of Prolonged Hypertrophic Resistance Training on Acute Endocrine Responses in Young and Older Men

2015 ◽  
Vol 23 (2) ◽  
pp. 230-236 ◽  
Author(s):  
Simon Walker ◽  
Fabrizio Santolamazza ◽  
William Kraemer ◽  
Keijo Häkkinen
Keyword(s):  
Growth Hormone ◽  
Resistance Training ◽  
Endocrine System ◽  
Exercise Bout ◽  
Older Men ◽  
Exercise Protocol ◽  
Acute Responses ◽  
Before And After ◽  
Serum Hormone ◽  
Hormone Responses

The present study investigated changes in acute serum hormone responses to a resistance exercise bout following a prolonged period of hypertrophic resistance training in young (YM) and older men (OM). Subjects performed a 5 × 10RM leg press exercise protocol before and after 20 weeks of hypertrophic resistance training. In YM, the acute responses in growth hormone were greater compared with before training (p < .05), and cortisol concentration did not increase after training. Endocrine responses in OM were similar before and after training. Greater acute growth hormone responses after training were associated with larger gains in lean mass in the entire subject group (r = .596, p = .019). These findings suggest that, in general, YM demonstrate greater adaptability within the endocrine system compared with OM. However, adaptability in growth hormone response was associated with larger training-induced gains independent of age.

Possible Involvement of Dopaminergic Mechanisms in the Antimigraine Action of Flunarizine

Cephalalgia ◽  
1990 ◽  
Vol 10 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Paola Piccini ◽  
Angelo Nuti ◽  
Anna Maria Paoletti ◽  
Alessandro Napolitano ◽  
Gian Benedetto Melis ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Prophylactic Treatment ◽  
Thyrotropin Releasing Hormone ◽  
Extrapyramidal Side Effects ◽  
Releasing Hormone ◽  
Dopaminergic Systems ◽  
Dopaminergic Mechanisms ◽  
Before And After ◽  
Hormone Responses ◽  
Prolactin Response

Flunarizine, a calcium antagonist widely used in the prophylactic treatment of migraine, may interfere with dopaminergic systems. Flunarizine therapy can in fact induce extrapyramidal side effects and can increase basal as well as stimulated prolactin levels. To better define the mechanism of flunarizine action in migraine, we studied prolactin and growth hormone responses to thyrotropin releasing hormone and sulpiride in 13 female migraineurs before and after 60 days of flunarizine therapy. The treatment did not modify basal prolactin and growth hormone levels, but prolactin response to thyrotropin releasing hormone was enhanced. A paradoxical increase of growth hormone to thyrotropin releasing hormone observed before therapy was blunted after flunarizine treatment. These data indicate a modulatory action of flunarizine on dopaminergic systems which might to some extent explain the antimigraine action of this drug.

Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients

1990 ◽  
Vol 28 (1) ◽  
pp. 73-78 ◽  
Author(s):  
Jeffrey L. Rausch ◽  
Stephen M. Stahl ◽  
Richard L. Hauger
Keyword(s):  
Growth Hormone ◽  
Depressed Patients ◽  
Hormone Responses
Sign in / Sign up

Export Citation Format

Share Document